Literature DB >> 15734959

Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.

Tor Molden1, Irene Kraus, Frank Karlsen, Hanne Skomedal, Jan F Nygård, Bjørn Hagmar.   

Abstract

The purpose of this study was to compare the detection of human papillomavirus (HPV) DNA with detection of mRNA. The study included 4,136 women >30 years of age. E6/E7 mRNA expression from the carcinogenic HPV types 16, 18, 31, 33, and 45 was detected by the PreTect HPV-Proofer assay, whereas the presence of HPV DNA was detected by Gp5+/6+ consensus PCR followed by type-specific PCR. A total of 4.0% had an abnormal cytologic diagnosis, 3.0% were positive by PreTect HPV-Proofer, 4.4% by type-specific PCR, and 10.4% by consensus PCR. For detection of HPV in high-grade squamous intraepithelial lesion (HSIL), no significant difference was observed between PreTect HPV-Proofer and consensus PCR. For women with a cytologic normal, atypical squamous cell of uncertain significance, and low-grade SIL diagnosis, the detection rate of HPV was significantly higher by Gp5+/6+ consensus PCR (P < 0.005) than by PreTect HPV-Proofer. Histology confirmed 14 of 23 cytologic HSIL as cervical intraepithelial neoplasia grade >2. Of these women, PreTect HPV-Proofer and type-specific PCR detected 12, whereas consensus PCR detected 13. In conclusion, for HSIL, detection of E6/E7 transcripts from HPV types 16, 18, 31, 33, and 45 are present to the same degree as DNA detected by consensus PCR. Equally important, only a small proportion of the HPV DNA-positive women with a normal, atypical squamous cell of uncertain significance or low-grade SIL diagnosis had a detectable mRNA expression. HPV E6/E7 mRNA detection by PreTect HPV-Proofer represents a new promising test as an adjunct to cytology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15734959     DOI: 10.1158/1055-9965.EPI-04-0410

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  32 in total

1.  Making biology learning relevant to students: integrating people, history, and context into college biology teaching.

Authors:  Katayoun Chamany; Deborah Allen; Kimberly Tanner
Journal:  CBE Life Sci Educ       Date:  2008       Impact factor: 3.325

2.  The value of improving failures within a cervical cancer screening program: an example from Norway.

Authors:  Emily A Burger; Jane J Kim
Journal:  Int J Cancer       Date:  2014-03-20       Impact factor: 7.396

3.  Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.

Authors:  Samuel Ratnam; Francois Coutlee; Dan Fontaine; James Bentley; Nicholas Escott; Prafull Ghatage; Veeresh Gadag; Glen Holloway; Elias Bartellas; Nick Kum; Christopher Giede; Adrian Lear
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

4.  High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.

Authors:  D C Rijkaart; D A M Heideman; V M H Coupe; A A T P Brink; R H M Verheijen; H Skomedal; F Karlsen; E Morland; P J F Snijders; C J L M Meijer
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

5.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

6.  Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing.

Authors:  Sveinung Wergeland Sørbye; Silje Fismen; Tore Gutteberg; Elin Synnøve Mortensen
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

7.  A comparison of human papillomavirus genotype-specific DNA and E6/E7 mRNA detection to identify anal precancer among HIV-infected men who have sex with men.

Authors:  Philip E Castle; Stephen Follansbee; Sylvia Borgonovo; Diane Tokugawa; Lauren M Schwartz; Thomas S Lorey; Brandon LaMere; Julia C Gage; Barbara Fetterman; Teresa M Darragh; Ana Cecilia Rodriguez; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-11-15       Impact factor: 4.254

8.  Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.

Authors:  Ameli Tropé; Katrine Sjøborg; Anne Eskild; Kate Cuschieri; Tormod Eriksen; Steinar Thoresen; Martin Steinbakk; Vigdis Laurak; Christine M Jonassen; Unni Westerhagen; Morten B Jacobsen; Agnes Kathrine Lie
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

9.  RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus.

Authors:  Paola Cattani; Alessia Siddu; Sara D'Onghia; Simona Marchetti; Rosaria Santangelo; Valerio G Vellone; Gian Franco Zannoni; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

10.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.